Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421086 | 0.97 | F2 (0.66) | F2OPRM1ACEOPRD1OPRK1 | |
| SCHEMBL30443402 | 0.94 | F2 (0.69) | F2OPRM1ACEOPRD1OPRK1 | |
| SCHEMBL29421094 | 0.94 | F2 (0.69) | F2OPRM1ACEOPRD1OPRK1 | |
| SCHEMBL29391128 | 0.87 | F2 (0.55) | F2OPRM1OPRD1OPRK1 | |
| SCHEMBL31412199 | 0.87 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL29702054 | 0.87 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL30833622 | 0.87 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL31167614 | 0.87 | OPRM1 (0.75) | F2OPRM1OPRD1SLC6A2 | |
| SCHEMBL30721707 | 0.86 | F2 (0.71) | F2OPRM1OPRD1SLC6A2 | |
| SCHEMBL29349609 | 0.86 | POLB (0.68) | F2OPRM1OPRD1OPRK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4079316-A1 | PROCOAGULANT COMPOUNDS | Bioverativ Therapeutics Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220243189-A1 | PROCOAGULANT COMPOUNDS | BIOGEN MA INC. | 2022-08-04 | — | — | US | disclosed |
| EP-3693000-B1 | PROCOAGULANT COMPOUNDS | BIOVERATIV THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220243189-A1 | PROCOAGULANT COMPOUNDS | PLG, F2, PLAT | F2 2/4885OPRM1 4367/4885ACE 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.